Her daughter Ella-Rose has Friedreich’s ataxia, a rare, progressive neurological condition which has affected her balance, coordination and mobility, leaving her increasingly reliant on a wheelchair.

Ms Kennedy has developed a detailed proposal, called RARE, which would bring together specialist doctors, pharmacists and NHS decision-makers to help patients identify the treatment options available to them.

The proposed six-month pilot has an illustrative budget of between £52,000 and £97,000, excluding the cost of medicines and treatment.

It would aim to provide an initial assessment within 10 working days and a written treatment-access plan within 30 working days, where clinically feasible.

The scheme would not automatically grant patients access to medicines or bypass existing approval processes, but would seek to make decisions quicker, clearer and more consistent across Scotland.

READ MORE:

Speaking to The Herald, Ms Kennedy said: “We haven’t got time to wait months and months and months to get access to these medications. Time is decline.”

She believes Scotland could lead the way in developing a more coordinated approach to rare-disease treatment.

“I just thought they could trial it out in Scotland and see how it goes,” she said.

Ms Kennedy has shared her proposals with MSPs from several parties, the Scottish Government’s Rare Disease Team, the Scottish Medicines Consortium and Ataxia UK.

However, she confirmed she has not yet received a formal response from the Scottish Government specifically addressing whether it would consider the pilot.

She added: “I feel strongly that there are gaps in the current system, and I don’t want to simply highlight the problems without trying to offer a practical solution.”

The campaign has been inspired by Ella-Rose’s experience of living with Friedreich’s ataxia.

Ella-Rose was diagnosed in November 2024, aged eight, after her parents noticed she was gradually losing abilities she had previously developed.

Once an active little girl who enjoyed swimming, gymnastics, dancing and riding her bike, she began experiencing increasing difficulties with balance and coordination.

Her handwriting deteriorated, while fatigue and problems with movement began affecting her everyday life.

Her mother said Ella-Rose now uses a wheelchair more frequently, although the family works to keep her active through physiotherapy and exercise.

Ella-Rose Kennedy, 10, was diagnosed with Friedreich’s ataxia aged eight after her family noticed she was losing skills she had previously developed, including riding her bike and taking part in gymnastics. (Image: Supplied)

Despite her challenges, she describes her daughter as determined, kind and optimistic, and excited about starting secondary school.

“She’s very determined. She’s a very kind wee girl,” Ms Kennedy said.

Ella-Rose began taking part in the BRAVE paediatric clinical trial of Skyclarys, a medicine for Friedreich’s ataxia, in Germany in July after the UK trial was paused.

She had initially undergone screening in London before her family was told the study would no longer proceed there.

Determined to secure another opportunity, Ms Kennedy asked whether Ella-Rose could participate at a trial centre in Germany.

“I’d travel to the moon for my daughter if it meant that she could do this,” she recalled telling her daughter’s clinician.

The family initially travelled to Germany every month, with pharmaceutical company Biogen covering flights and accommodation.

The first year of the study is blinded, meaning Ella-Rose could be receiving either Skyclarys or a placebo.

Her mother has noticed some encouraging changes, including fewer tremors and reports of less tiredness at school, although she cannot establish whether these are linked to the trial treatment.

The family has been reassured that continued access to the medicine may be possible after the trial if Ella-Rose benefits and tolerates it, but questions remain over how this would work in practice.

Skyclarys received UK regulatory approval in April 2025 for patients aged 16 and over, but was not recommended for routine NHS use in Scotland by the Scottish Medicines Consortium in March 2026.

The SMC acknowledged evidence of clinical benefit but concluded that the treatment’s cost relative to its benefits had not been sufficiently justified.

Ms Kennedy fears other families could face similar difficulties whenever new treatments for rare conditions become available.

She also questioned how well existing medicine access routes are understood, claiming Ella-Rose’s neurologist had been unfamiliar with PACS Tier 2, a process through which clinicians can request medicines that are not routinely available.

Her RARE proposal would seek to address such problems by providing patients with a named NHS contact, specialist input and clear written information about possible treatment routes.

It would also encourage earlier planning for patients approaching the end of clinical trials, so families have a clearer understanding of their options for continuing treatment.

Ms Kennedy said Ataxia UK had responded positively to elements of her proposal, with further discussions anticipated about how the ideas could complement the charity’s existing work.

She has also been in contact with several politicians, including Adam Harley MSP, who raised Ella-Rose’s situation with First Minister John Swinney in September.

Ms Kennedy stressed that the proposed pilot would cover adults as well as children and people living with a wide range of rare conditions.

She and her husband have also established a charity, Here & Now – Children’s Rare Disease Support, to offer practical and emotional support to affected families, initially across West Lothian and the Lothians.

The charity is preparing for its official launch on March 28, 2027.

Ms Kennedy hopes that raising awareness of Ella-Rose’s condition will help bring about wider changes for families facing similar challenges.

She told The Herald: “I want to show that behind every policy, appraisal decision and funding discussion are real people and families.”

She added: “For people living with progressive conditions, time is precious.”

Lib Dem health spokesperson and MSP Adam Harley has raised the concerns with the First Minister.

Mr Harley said: “When Ella-Rose’s case was raised with me, I knew that this was something that needed urgent attention.

“We are seeing promising results from clinical trials and new gene therapies could potentially transform lives but without a clear pathway for Scots to access these advances, too many will miss out.

“I raised with the First Minister the importance of this pathway and I hope he will listen to Jenny and Ella Rose’s pleas and take the necessary steps so that patients won’t have to fight against the system to get care.”

The Scottish Government was asked whether ministers will consider a feasibility assessment of the proposed six-month RARE pilot and what action is being taken to improve access to treatments for people with rare diseases.

A Scottish Government spokesperson said: “The Scottish Government is committed to increasing the availability of medicines, including those for rare conditions such as Friedreich’s ataxia.

 “Decisions on treatment access are made through shared discussions between individuals, families and the clinicians in charge of care who are best placed to advise on available medicine access pathways, including options that may be available when an individual has participated in a clinical trial.

 “Biogen has provided assurance that it will continue to explore all options to support routine access to Omaveloxolone in the NHS in Scotland. The decision on whether to resubmit to the Scottish Medicines Consortium (SMC) and the timing of that resubmission rests entirely with Biogen.”